109 results
Page 5 of 6
6-K
EX-99.1
3ghbkwbvae9
18 Jun 19
Patent Covering Manufacturing Process of BiondVax’s M-001 Universal Flu Vaccine Allowed in USA and Japan
9:23am
F-1/A
8vwxga1plve3b58j
7 Jun 19
Registration statement (foreign) (amended)
11:42am
F-1/A
xkrjm1hixq3bjf9qva
6 Jun 19
Registration statement (foreign) (amended)
12:00am
6-K
EX-99.1
v747y4lay0m zudvqi
30 May 19
BiondVax Announces First Quarter 2019 Financial Results
9:46am
F-1/A
1lvpa c64
30 May 19
Registration statement (foreign) (amended)
8:46am
F-1/A
kkmzx3 4w6
6 May 19
Registration statement (foreign) (amended)
10:03am
6-K
EX-99.1
hrm905kbewxrt11mij
1 May 19
BiondVax Announces Fourth Quarter and Full Year 2018 Financial Results and Update
6:23am
6-K
EX-99.1
eck0m
22 Apr 19
Report of Foreign Private Issuer
10:03am
6-K
EX-99.1
avdql1a43j7y
8 Apr 19
Report of Foreign Private Issuer
7:00am
6-K
EX-99.1
8h0m44zl
27 Mar 19
Current Report of Foreign Issuer
4:02pm
F-1
t4joi6 xu
25 Mar 19
Registration statement (foreign)
4:08pm
6-K
EX-99.1
ylfvif44ymg
14 Nov 18
Third Quarter 2018 Financial Results
7:30am
6-K
EX-99.1
26fyi a3u
29 Oct 18
BiondVax’s Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season’s Enrollment of 4,098 Participants
6:18am
6-K
EX-99.1
f8w smw52oh
23 Oct 18
BiondVax receives €8M from the European Investment Bank (EIB) in support of manufacturing facility and ongoing Phase 3 clinical trial
4:02pm
6-K
EX-99.1
57s1kzgaha54bvgre1y0
16 Aug 18
BiondVax receives second €6M tranche disbursement
4:06pm
6-K
EX-99.1
l8ovmy8 9a1r
10 Aug 18
Report of Foreign Private Issuer
3:30pm
6-K
EX-99.1
eymzf2f2
28 Jun 18
Corporate Biotech Executive Mark Germain Joins BiondVax’s Board of Directors
9:20am
6-K
kg1457cobzjkfh0
25 Jun 18
BiondVax receives its first €6M tranche disbursement
4:16pm
6-K
EX-99.1
khoimt3jkyg00d
25 Jun 18
BiondVax receives its first €6M tranche disbursement
4:16pm